samedan logo
home > news > detailed info

BioIVT Appoints Alan Findlater as Chief Commercial Officer


BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing and customer service.

“Alan is a visionary leader with the requisite knowledge and experience to help guide BioIVT on its rapid growth trajectory as we continue to be the trusted leader for biological products and services,” said BioIVT Chief Executive Officer Jeffrey Gatz. “Alan has successfully built and led global sales, marketing and commercial operation teams at several major organizations, and his strong services sales background aligns closely with our recent acquisitions. Equally important, he shares BioIVT’s commitment to excellent customer service and product quality. I am delighted to welcome Alan to our executive team.”

BioIVT has acquired five companies – Asterand Bioscience, Qualyst Transporter Solutions, Optivia Biotechnology, Ascendance Biotechnology, and Clinical Trials Laboratory Services – since August 2017.

“BioIVT is at an exciting inflection point in its development due to a surge in demand for its research models and services. For example, the healthcare industry’s increasing focus on personalized medicine is resulting in a corresponding increase in patient screening and specimen inclusion/exclusion criteria for preclinical development. This is creating a need for more specialized biospecimens, with comprehensive clinical data, to test new drug candidates for safety and efficacy,” said Mr. Findlater.

Mr. Findlater has more than 33 years’ experience in the pharmaceutical, medical device, and R&D services sectors. He was chief commercial officer at WIL Research Laboratories for more than five years before it was acquired by Charles River Laboratories in April 2016.

Mr. Findlater was appointed Charles Rivers’ executive director, global business development, safety assessment, discovery and research models post-acquisition and led the commercial integration of both WIL Research Laboratories and Agilux discovery services.

Prior to that, Mr. Findlater held several senior global management positions at Covance Laboratories Inc., culminating in global vice president of sales and client services Early Pharmaceutical Development.

Mr. Findlater has a bachelor’s degree in chemistry from the University of Strathclyde and a master’s degree in business administration from the University of Warwick Business School, UK.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit or follow the company on Twitter @BioIVT.
phone +1 516 483 1196
email PO Box 770, Hicksville, NY, 11802-0770
Print this page
Send to a friend
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement